9. Evaluation of Synergy Testing Methods for Clinical Labs to Determine Susceptibility of Extensively Drug-resistant Gram-negatives to Ceftazidime/ Avibactam and Aztreonam Combination Therapy

BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CR-PA) producing Metallo-β-lactamases (MBLs) cause severe nosocomial infections with no defined treatment. Combination therapy with ceftazidime/ avibactam (CZA) and aztreonam (ATM) is a potential option, but there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Ayesha, Erickson, Samuel G, Pettaway, Cedric H, Arias, Cesar A, Miller, William R, Bhatti, Micah M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776012/
http://dx.doi.org/10.1093/ofid/ofaa417.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776012/
http://dx.doi.org/10.1093/ofid/ofaa417.008

Ejemplares similares